Russia's Sputnik V vaccine is 91.6% effective against symptomatic Covid-19, according to results published today that independent experts said allayed transparency concerns over the jab, which Moscow is already rolling out.
Sputnik V - named after the Soviet-era satellite - was approved in Russia months before results from its final-stage clinical trials were published, leading to scepticism from experts.
But the new analysis of data from 20,000 Phase 3 trail participants, published in The Lancet medical journal, suggests that the two-dose vaccination offers more than 90% efficacy against symptomatic Covid-19. "The development of the Sputnik V vaccine has been criticised for unseemly haste, corner cutting, and an absence of transparency,"